Semaglutide 2.0mg: where this dose fits in the Wegovy schedule

Step 1: understanding semaglutide's two separate dose ladders

Semaglutide is the active ingredient in both Wegovy (weight management) and Ozempic (type 2 diabetes). They share the molecule but not the dose schedule. Ozempic's maintenance dose reaches 2.0mg for some patients with diabetes, which is why 2.0mg semaglutide appears in clinical literature and, from there, in search results. Wegovy's highest maintenance dose is 2.4mg, meaningfully different, and arrived at through a separate, slower titration designed around tolerability for people without diabetes. The two products are not interchangeable, and the MHRA licenses each for its own indication. A question our prescribers hear most weeks is whether a person can simply use Ozempic for weight loss because it contains the same drug. The honest answer is no: Ozempic is not licensed for weight management in the UK, and any prescriber issuing it for that purpose would be acting outside the terms of its authorisation. The NHS medicines guidance on semaglutide covers both products but is clear about which indication applies to which.

If you have been on Ozempic for diabetes and are now being considered for Wegovy, that is a separate clinical decision your prescriber will guide. The dose you end up on for weight management is determined by tolerability and response, not by what you were on for diabetes. For younger patients, Wegovy pediatric dosing follows its own separate clinical framework, which your prescriber will discuss if relevant.

Step 2: what the Wegovy titration schedule is designed to do

The Wegovy weight-management schedule, as set out in the NHS semaglutide medicines page, begins at 0.25mg for the first four weeks. That starting dose is there to let your body adjust, not to produce weight loss. The 0.5mg and 1.0mg steps follow at roughly four-week intervals; 1.7mg is the penultimate rung; 2.4mg is the standard maintenance dose. The 1.7mg step is sometimes the one people are on when they describe their dose loosely as "nearly 2mg", which may be another source of the 2.0mg confusion online.

Side effects are most noticeable in the first weeks of each new dose: nausea, loose stools, reduced appetite, and occasional fatigue. Most people find these settle within a fortnight. The prescriber can hold a dose for an extra four weeks if tolerability is poor, which is exactly the kind of clinical judgement that makes the titration a conversation rather than a fixed timetable. The pace is never self-directed.

For a full overview of how Wegovy works as a treatment, including how GLP-1 receptor agonism slows gastric emptying and reduces appetite signalling, the Wegovy pillar covers the mechanism in detail.

Step 3: what the clinical trial evidence shows at maintenance doses

The STEP 1 trial, published in the New England Journal of Medicine, ran for 68 weeks with adults taking 2.4mg semaglutide alongside lifestyle support. Average body-weight reduction was around 15%. That evidence base underpins the NICE recommendation for semaglutide (TA875), which sets out that treatment should be provided within a specialist weight management service for a maximum of two years. NICE also specifies that if less than 5% weight loss has occurred after six months at the maintenance dose, the case for continuing should be reviewed.

A newer, higher dose (7.2mg, approved by the MHRA in January 2026 as a higher maintenance option) has since expanded the Wegovy schedule beyond 2.4mg for eligible adults with BMI of 30 or above. If you are curious about whether that option might eventually be relevant to you, that is a conversation for the prescriber assessing your treatment. You can read more about the 2.0mg step in Wegovy's schedule context and how it relates to neighbouring doses.

Because these are prescription medicines, suitability for each dose and each change is assessed clinically. If you would like to explore whether Wegovy is right for your situation, the place to start is a free consultation with our prescribers.

Step 4: a note on safety, sourcing, and the 2.0mg confusion in the grey market

The fact that 2.0mg semaglutide appears in legitimate clinical contexts (Ozempic for diabetes) has made it a label some unregulated sellers use. The MHRA has warned repeatedly about semaglutide products sold without a prescription through social media and unverified websites. Fake pens have been found to contain insulin or other unknown substances. If you encounter a seller offering a 2.0mg semaglutide pen for weight loss, that is a meaningful red flag: no such product is licensed for weight management in the UK. You can report suspect sellers at the MHRA's Yellow Card scheme. Any pharmacy dispensing Wegovy legitimately can be verified on the GPhC register.

For background on how the wider treatment landscape looks, including comparing weight-loss treatment options, our weight-loss overview is a useful starting point. And if you want to understand the specific dose you have been prescribed, the 1.0mg step and the 1.7mg step each have their own dedicated pages. Our clinical team reviews every consultation personally, no algorithm involved.